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Abstract: Aldosterone is considered to exert direct effects on the
myocardium and the sympathetic nervous system. Both QT time and
heart rate (HR) variability (HRV) are considered to be markers ofD, Julia Wetzel, C a, MD, PhD,
eas Tomaschitz, MD, and Stefan Pilz, MD, PhD
We recruited 477 hypertensive patients (age: 60.2 10.2 years; 52.3%
females) with a mean systolic/diastolic 24-hour ambulatory blood pres-
sure monitoring (ABPM) value of 128 12.8/77.1 9.2 mmHg and with
a median of 2 (IQR: 1–3) antihypertensive agents. Patients were recruited
from the outpatient clinic at the Department of Internal Medicine of the
Medical University of Graz, Austria. Blood samples, 24-hour HRV
derived from 24-hour blood pressure monitoring (ABPM) and ECG’s
were obtained. Plasma aldosterone and plasma renin concentrations were
measured by means of a radioimmunoassay. Twenty-four-hour urine
specimens were collected in parallel with ABPM.
Mean QTc was 423.3 42.0 milliseconds for males and
434.7 38.3 milliseconds for females. Mean 24H-HR and 24H-HRV
was 71.9 9.8 and 10.0 3.6 bpm, respectively. In linear regression
analyses adjusted for age, sex, body mass index, ABPM, and current
medication, aldosterone to active renin ratio (AARR) was significantly
associated with the QTc interval, a marker for cardiac repolarization
abnormalities (mean¼ 426 42.4 milliseconds; b-coefficient¼ 0.121;
P¼ 0.03) as well as with the 24-hour heart rate variability a surrogate
for autonomic dysfunction (median¼ 9.67 [IQR¼ 7.38–12.22 bpm]; b-
coefficient¼0.133; P¼ 0.01).
In hypertensive patients, AARR is significantly related to QTc
prolongation as well as HRV. Further studies investigating the effects
of mineralocorticoid receptor blocker and aldosterone synthase inhibitors
on QTc and HRV are warranted.
(Medicine 95(8):e2794)
Abbreviations: 24H-HRV = 24-hour heart rate variability, AARR
= Aldosterone to active renin ratio, ABPM = 24-hour ambulatory
blood pressure monitoring, ACE = angiotensin converting enzyme,
AF = atrial fibrillation, AT1 = angiotensin II type one, BMI = body
mass index, BP = blood pressure, CV = cardiovascular, eGFR =
estimated glomerular filtration rate, HR = heart rate, HRV = heart
rate variability, MDRD = Modification of Diet in Renal Disease,
MR = mineralocorticoid receptor, MRA = mineralocorticoid
receptor antagonist, PA = primary aldosteronism, PAC = plasma
aldosterone concentrations, PRC = plasma renin concentration,
RIA = radioimmunoassay.
INTRODUCTION
A ldosterone is secreted by the adrenal glands and is classi-cally known to contribute to the regulation of salt and fluid
homeostasis. It is further considered to assume functions of a
growth factor,1 that could potentially mediate actions of
relevance to heart failure, myocardial infarction, and arterialover, it is possibly involved in patho-
s that lead to atherosclerosis, endothelial
ricular remodeling.5,6 In particular, the
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myocardium appears to be a target tissue for aldosterone, as
animal studies and in vitro experiments have documented
remodeling of cardiomyocytes when exposed to excessive
aldosterone levels.7–9 The proposed mechanisms mediating
the link between aldosterone, the mineralocorticoid receptor
(MR) and cardiovascular (CV) mortality involve genomic and
nongenomic effects.9–12 The latter fits with the observation that
there is functional cross-talk between aldosterone and various
growth factor receptor signaling pathways within cardiac tis-
sue.7–9,12–14 This is of particular importance given that the
effects on cellular remodeling have been demonstrated to be a
major underlying mechanism for the development of suscepti-
bility to arrhythmias.15 While the precise mechanisms are still
largely unknown, it is possible that increased aldosterone might
be directly related to negatively influencing myocardial inflam-
mation and fibrosis.3,11,16 Previous studies described an associ-
ation between aldosterone and adrenergic tone.17,18
Nevertheless, the association between aldosterone and surro-
gate markers of autonomic dysfunction and sudden cardiac
death in patients with arterial hypertension remain to be fully
elucidated. Both QTc and heart rate variability (HRV) are
known to be associated with arrhythmic risk in patients with
arterial hypertension.19–24 In this study, we therefore aimed to
examine the association between aldosterone (as a ratio to renin,
as both represent 2 ends of a continuous spectrum)25–27 and
QTc interval as well as with 24-hour HRV (24H-HRV).
METHODS
Details of the Styrian Hypertension Study have been pre-
viously published.28,29 We invited patients with a history of
arterial hypertension, that is, either arterial hypertension accord-
ing tomedical records or according to patient interview. All study
participants (age 18 years) were prospectively recruited at the
Department of Internal Medicine at the Medical University of
Graz, Austria and received 24-hour blood pressure monitoring
(Figure 1). We examined 477 patients in total with a mean age of
60.9 10.6 years (52.3% female). Exclusion criteria were stroke
or myocardial infarction in the previous 4 weeks, pregnancy and
lactation, and an estimated life expectancy of less than 1 year, as
Gru¨bler et alper assessment by a senior physician. Written informed consent
was provided from all study participants. The Styrian Hyperten-
sion Study was approved by the ethics committee at the Medical
FIGURE 1. Consort 2010 Study flow chart describing the process
of recruiting patients and their assessment.
2 | www.md-journal.comUniversity Graz, Austria. The study is compatible with the
Declaration of Helsinki (October 2013) and the STROBE guide-
lines in regard to reporting cross-sectional studies.
Circumference of the upper arm was measured in all
patients to select the appropriate cuff for blood pressure (BP)
measurements. ABPM was performed with a SPACELABS
90217A device (firmware version: 03.02.16; Spacelabs Health-
care, Inc, Issaquah, WA) at 15-minute intervals during the day
(06:00–22:00 AM) and every 30minutes during the night
(22:00–06:00 AM). In parallel, 24-hour urine specimens were
obtained from the study participants. 24H-HRV was defined as
the standard deviation of 24-hour heart rate obtained by ABPM
measurement. This method can also be referred to as SDNN
(standard deviation of normal to normal beats), measured every
15minutes during the day and every 30minutes during night-
time. QT time was measured on 50 and 100mm/second ECG
recordings by a single investigator masked to patient charac-
teristics. The ECG was obtained in the morning between 7 and
11 PM at the beginning of the 24-hour period of ABPM
measurement. An additional sample was recorded randomly
by a second independent investigator for validation purposes.
The corrected QT time was calculated according to Framing-
ham: QTc¼QTþ 0.154 (1RR).30 All ECG measurements
were performed by adhering to published guidelines.31
Laboratory Measurements
Blood samplings were performed in the morning (07:00–
11:00 AM) after an overnight fast and after ten minutes of rest in
the seated position. All blood samples were either measured at
least within 4 hours after sampling or were immediately stored
at 208C until analysis. Plasma renin concentrations (PRC)
were measured in EDTA plasma by a ‘‘RENIN III GENER-
ATION’’ (GEN. III) radioimmunoassay (RIA) (Renin IRMA
RIA-4541, DRG Instruments GmbH, Marburg, Germany).
Plasma aldosterone concentrations (PAC) were also determined
by means of a RIA (Aldosterone RIA DSL-8600, Diagnostic
Systems Laboratories, Inc., Webster, TX). Aldosterone-to-
active renin concentration was calculated as PAC divided by
PRC (ng/dl divided by mU/ml). Estimated glomerular filtration
rate (eGFR) was calculated according to the Modification of
Diet in Renal Disease (MDRD) formula. All other measure-
ments (eg, sodium, potassium, calcium, c-reactive protein
[CRP], etc.) were performed by routine laboratory procedures.
Statistical Methods
The distribution of continuous variables was evaluated
and, where appropriate, nonnormally distributed variables were
log10-transformed and indicated in the text with the prefix
‘‘log.’’ For baseline characteristics we formed quartiles accord-
ing to the aldosterone to active renin ratio (AARR) values of the
overall study cohort. There was no data imputation and patients
with missing values were excluded from the main analysis.
Group comparisons were performed either by Chi-square test,
analyses of variance (ANOVA), or Kruskal–Wallis test, when
appropriate. To test the assumption of a linear regression
analysis between the dependent and independent variables of
interest we plotted the residuals (observed vs. predicted values)
and tested for colinearity for all included parameters (criteria
were variance inflation factor <1.96 equivalent to tolerance
>0.51). We performed linear regression analyses to evaluate the
Medicine  Volume 95, Number 8, February 2016association between QTc or 24H-HRV (dependent variables)
and AARR (independent variable). Cumulative adjustments
were performed for various confounders that were prudently
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
selected based on their suspected interaction with the renin–
angiotensin–aldosterone system, QT time, and 24H-HRV.
Three models were built, based on increasing explanatory value.
Model 1 included log age (years) and gender. Model 2 addition-
ally included log body mass index (BMI) (kg/m2), current
smoking status (yes/no), eGFR-MDRD (ml/min/1.73m2),
HbA1c (mmol/mol), systolic and diastolic 24-hour BP (mmHg),
and urinary sodium/potassium (Naþ/Kþ) ratio. In Model 3,
treatment with binary variables for use of b-blockers (yes/no),
angiotensin converting enzyme (ACE)-inhibitors (yes/no),
angiotensin II type one (AT1) receptor blockers (yes/no),
calcium channel blockers (yes/no), loop diuretics (yes/no)
and thiazides (yes/no) were included. Patients under treatment
with mineralocorticoid receptor antagonist (MRA) and atrial
fibrillation (AF) on current ECG were excluded from the
present analyses, as AF diminishes the interpretation of the
QT interval.31 In additional analysis, further adjustments for
Medicine  Volume 95, Number 8, February 2016calcium (mmol/L), potassium (mmol/L), phosphate, 25-
hydroxy-vitamin-D (ng/ml), nocturnal blood pressure (mmHg),
and CRP (mg/L) were made. We repeated the analysis using a
TABLE 1. The Baseline Characteristics According to Aldosterone
Variable 1st Quartile
Aldosterone range, ng/dl 0.03–0.3
Number of patients (total¼ 477) 116
Age, yr 62.0 11.65
BMI, kg/m2 30.9 4.6
QTc Framingham, ms 419 34
Mean 24-h heart rate variability, bpm 9.79 3.48
Mean 24-h heart rate, bpm 70.8 14.4
Heart rate during nighttime, bpm 63.1 12.7
Heart rate variability during nighttime, bpm 4.10 (2.70–5.17) 3
Blood pressure
Daytime systolic BP, mmHg 129.9 11.4
Nighttime systolic BP, mmHg 115.9 13.5
Daytime diastolic BP, mmHg 75.7 8.5
Nighttime diastolic BP, mmHg 65.3 7.6
24 h urinary sodium, mmol/24 h 165.0
(116.0–217.5)
C-reactive protein, mg/dl 2.37 3.01
Serum potassium, mmol/L 4.12 0.39
Serum calcium, mmol/L 2.39 0.12
Serum phosphate, mg/dl 2.97 0.48
25-Hydroxyvitamin D, ng/ml 26.91 11.45
GFR-MDRD, ml/min/1.73 m2 71.2 19.8
Diabetes mellitus, % 34.0
Active smokers, % 3.7
Medication
Number of different antihypertensive drugs 2 (1–3)
ACE-I, % 49.0
AT1 blocker, % 39.2
b-blocker, % 45.3
Calcium channel blockers, % 30.2
Thiazide diuretics, % 50.8
Loop diuretics, % 13.3
MRA, % 1.9
Continuous data are presented as means standard deviation or as media
ANOVA with P for trend, Kruskal–Wallis and Chi-square test were used.
ACE¼ angiotensin converting enzyme, AT1¼ angiotensin II type one, BM
rate, MDRD¼Modification of Diet in Renal Disease, MRA¼mineralocor
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.multiplicative interaction term of HR and HRV as well as
including only those with an HR ranging between 60 and
70 bpm32–34 in order to account for the fact that higher/lower
HRs are intrinsically linked to changes in HRV.32–34 In an effort
to exclude the potential that our results may reflect changes
typically known in patients with primary aldosteronism (PA),
we repeated the analyses in patients with a negative screening
result for PA (AARR< 3.7 ng/dl/mU/ml). As a sensitivity
check, participants with a renin level below 5mU/ml (detection
limit of the assay) were omitted in an attempt to control for
flawed interpretations of the AARR as well as patients with low-
renin hypertension, which is considered to resemble a mild form
of PA. All statistical analyses were performed using SPSS 20
(SPSS, Inc., Chicago, IL) and a 2-sided P-value< 0.05 was
considered statistically significant.
RESULTS
Aldosterone, QTc Prolongation, and Changes in HRVMean QTc corrected by the Framingham equation was
423.3 42.0 milliseconds for males and 434.7 38.3 millise-
milliseconds for females (Table 1, showing the baseline
–Renin Ratio Quartiles
2nd Quartile 3rd Quartile 4th Quartile P
0.32–0.83 0.85–1.72 1.73–13.26
123 122 116
61.3 8.1 57.0 10.0 60.0 11.0 0.04
30.0 4.7 29.8 4.6 28.6 5.1 0.03
429 39 416 37 440 48 0.02
10.0 3.59 10.30 3.53 9.64 3.73 0.45
69.7 8.8 71.8 9.2 70.8 9.7 0.57
62.5 8.2 64.5 9.1 63.6 8.8 0.69
.80 (3.08–5.20) 3.87 (2.83–5.34) 3.69 (2.83–5.63) 0.97
127.5 13.9 134.4 14.2 132.6 12.9 0.04
116.0 15.0 119.2 16.0 119.0 13.6 <0.01
78.8 8.4 81.5 8.1 81.4 11.0 0.49








3.26 4.29 2.55 2.83 3.31 3.78 0.03
4.04 0.30 3.99 0.34 4.02 0.32 0.02
2.37 0.11 2.38 0.11 2.38 0.09 0.30
2.97 0.49 2.95 0.50 3.03 0.52 0.59
29.05 12.04 28.38 11.81 28.73 10.97 0.52
72.4 13.6 78.6 18.7 79.2 17.5 0.04
22.6 17.0 15.4 0.09
9.4 20.8 25.0 <0.01
2 (1–3) 1 (1–3) 2 (1–3) 0.08
43.4 34.0 40.4 0.46
35.9 18.9 17.3 0.01
54.7 50.9 63.5 0.29
21.1 27.1 19.8 0.33
38.6 37.0 36.2 0.06
3.9 2.4 0.8 n.p.
3.9 0.0 0.0 n.p.
ns with interquartile range. Categorical data are shown as percentages.
n.p. indicates insufficient cell size to reliable test all quartiles.
I¼ body mass index, BP¼ blood pressure, GFR¼ glomerular filtration
ticoid receptor antagonist.
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The mean QTc was statistically significant different
between the quartiles (Figure 3) in the unadjusted ANOVA.
QTc Framingham prolongation was significantly associated
TABLE 2. Linear Regression Modeling
24 h Heart Rate Variability QTc
b-Coefficient P b-Coefficient P
Model 1 070 0.11 0.144 <0.01
Model 2 153 <0.01 0.119 0.02
Model 3 133 0.01 0.121 0.03
þ CRP 128 0.01 0.116 0.05
þ Serum potassium 133 0.01 0.115 0.05
þ Serum phosphate 134 0.01 0.113 0.04
þ Serum calcium 131 0.01 0.120 0.05
þ 25-hydroxy Vit D 134 0.01 0.129 0.04
þ Nocturnal systolic BP 131 0.01 0.118 0.03
Model 3 using an interaction term of heart rate
and heart rate variability
0.142 0.063 — —
Model 3 in patients with heart rate 60–70/min 0.074 0.36 0.238 <0.01
Model 1 included age (years) and gender. Model 2 additionally included log body mass index (BMI) (kg/m2), current smoking status (yes/no),
eGFR-MDRD (ml/min/1.73 m2), HbA1c (mmol/mol), systolic and diastolic 24-h BP (mmHg), and urinary sodium/potassium (Naþ/Kþ) ratio. In
Model 3, treatment with binary variables for use of b-blockers (yes/no), angiotensin converting enzyme (ACE)-inhibitors (yes/no), angiotensin II type
one (AT1) receptor blockers (yes/no), calcium channel blockers (yes/no), loop diuretics (yes/no) and thiazides (yes/no) were included. A P values
tatis
Gru¨bler et al Medicine  Volume 95, Number 8, February 2016characteristics according to aldosterone–renin ratio quartiles).
Mean 24H-HR and 24H-HRV was 71.9 9.8 and 10.0
3.6 bpm, respectively (Table 2).
Heart Rate Variability
The mean 24H-HRV was not statistically significant
different between the quartiles (Figure 2) in the unadjusted
ANOVA. AARR associations between 24H-HRV and AARR
according to the different regression models are reported in
Table 2 (Model 3: b-coefficient¼0.133; P¼ 0.01). Using
<0.05 is considered statistically significant.
BP¼ blood pressure, CRP¼C-reactive protein, Vit D¼ vitamin D.
Bold letters indicate a P-value of less than 0.05 and thus indicates srenin alone we observed a borderline statistically significant
association (b-coefficient¼ 0.102; P¼ 0.05), but not for
aldosterone (b-coefficient¼0.029; P¼ 0.53).
FIGURE 2. Mean 24-hour heart rate variability in each
aldosterone to active renin ratio quartile. Error bars indicate 1
standard deviation.
4 | www.md-journal.comQTc Interval
tical significance.FIGURE 3. Mean QTc time in each aldosterone to active renin
ratio quartile. Error bars indicate 1 standard deviation.
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with AARR irrespective of adjustment (Model 3: b-
coefficient¼ 0.121; P¼ 0.03). Considering renin and aldoster-
one separately, we did not observe a statistically significant
association for 24H-HRV (b-coefficient¼0.067; P¼ 0.25
and b-coefficient¼0.029; P¼ 0.53, respectively).
Sensitivity Analysis
The main results were similar when including only patients
with an AARR below 3.7 ng/dl/mU/ml or when excluding
patients with a renin level below the detection threshold
(5mU/ml, n¼ 42 patients). Repeating the analysis for HRV
using a multiplicative interaction term of HRHRV yielded
similar results as well as when only participants with an HR
between 60 and 70 bpm were included (Table 2).
DISCUSSION
In the present analysis we demonstrated an association
between reduced 24H-HRV, QTc prolongation, and aldoster-
one to renin ratio (ie, relative aldosterone excess) in patients
with arterial hypertension. These findings remained significant
after adjusting for a broad panel of confounders. The present
investigation supports and extends results of prior studies by
demonstrating a linear association between PAC with QTc
times as well as 24H-HRV. Our study is consistent with
previous investigations which point toward aldosterone
mediated proarrhythmic properties that might contribute to
CV morbidity and mortality in patients with hypertension and
is a therapeutic target.2,35 Intriguingly, both QTc and 24H-
HRV are significantly associated with aldosterone plasma
levels, possibly due to an interaction with autonomic tone
and consequently with arrhythmic risk.17,20,36–39 Ouvrard-
Pascaud et al40 published a transgenic mouse model suggesting
a role of MR activation in intrinsic rate and rhythm control.
Aldosterone mediated disorders of collagen turn-over might
represent one potential mechanism underlying MR-related
arrhythmic properties.41 The basic mechanism linking elevated
aldosterone levels to repolarization abnormalities might be
associated with increased myocardial capillary density,
increased accumulation of matrix proteins and higher mito-
chondrial levels of superoxide.7 Further, evidence from basic
research indicates interplay between MR activation and protein
expression of the NADPH oxidase subunits Nox2 and Nox4 as
well as changes in stress-induced NF-kB activation and thus
apoptosis in cardiomyocytes.3,7 There seem to be also changes
in calcium and potassium channel activity be involved.42,43
Interestingly, Santulli et al44 described in an animal model a
mutation of the ryanodine receptor (RyR), an important cause
of ventricular arrhythmias, is also associated with metabolic
alterations. In patients with heart failure, MRAs have been
shown to reduce the amount of premature ventricular beats,
QT interval, ventricular tachycardia, and ventricular fibrilla-
tion,45–47 which may be the case in arterial hypertension
as well.2,48,49 Matsumura et al50 previously described QTc
prolongation in 69 patients with PA. Another study
comprising 186 patients demonstrated longer QTc in those
with PA (434 23 milliseconds) and low renin hypertension
(430 18 milliseconds) as compared with essential hyperten-
sion (419 22 milliseconds).51 This study further supports our
use of the AARR instead of aldosterone or renin alone, especi-
ally as in both groups (PA and low renin hypertension) the
Medicine  Volume 95, Number 8, February 2016QT was similarly prolonged compared to essential hyperten-
sion.51 Albeit, these studies50–52 were limited by the relatively
small sample sizes. Further, most prior studies used QTc
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.corrected by Bazett, which is known to be limited due to over
and under-correction depending on HR.30,31,53 Our findings are
further strengthened by the use of 24-hour BP measurement
and by considering dietary salt intake, which strongly inter-
feres with the renin–aldosterone system.54 We used AARR
instead of plasma aldosterone or renin concentrations alone as
high aldosterone and low-renin status are 2 ends of a continu-
ous spectrum of relative and absolute aldosterone excess and
should not be investigated separately.25 Additionally, we
omitted patients with a renin level below the detection limit
(<5mU/ml) and with a positive screening result for PA, which
suggests that the findings are not mainly driven by patients with
Conn syndrome25,55 or due to a denominator phenomenon. We
therefore were able to demonstrate for the first time a con-
tinuous association between aldosterone to renin ratio and
prolonged QTc as well as reduced HRV in patients with
arterial hypertension.
LIMITATIONS
Our study consists of a group of hypertensive patients
recruited from outpatient clinics at a tertiary care hospital, thus
the current findings may not be applicable to the general
population. More so, the large majority of our patients were
under treatment with antihypertensive medication known to
interfere with the RAAS. To minimize the confounding, the
patients had to be on stable treatment for at least four weeks to
be included in the study. Though, it bears mentioning that our
cohort reflects patients typically seen in clinical practice.
Further, the lack of a normotensive control group limits the
present findings to patients with arterial hypertension. The
diurnal variation of aldosterone was not considered appropri-
ately by use of an 1-time measurement of morning plasma
concentrations. Nevertheless, previous studies demonstrated
that the overall 24-hour variation in aldosterone is low, especi-
ally compared with the suppression seen by high salt intake.56 In
an effort to improve comparability, blood sampling was sched-
uled during the morning hours.57 Both outcome parameters (ie,
QTc and 24H-HRV) might not necessarily reflect risk for hard
clinical endpoints (eg, mortality) and are not able to completely
measure autonomic nervous system dysregulation and intrinsic
cardiac automaticity.33,34,58,59 More so, we used the SD of
ABPM based 24-hour heart rate as a measure of 24H-HRV,
which differs according to ECG based HRV.33,34,58–60 Never-
theless HRV measured by ABPM (standard deviation of normal
to normal beats) has turned out to be a valid predictor of clinical
outcomes.61,62
CONCLUSIONS
We investigated the association of aldosterone to renin
ratio with surrogate markers of autonomous dysfunction and
sudden cardiac death, namely reduced heart rate variability and
prolonged QTc. In this study, AARR was found to be a strong
predictor of both prolonged QTc time and reduced 24H-HRV.
Considering that these associations may reflect a causal
relationship, we speculate that there might be a more favorable
effect (eg, arrhythmic risk reduction) of aldosterone blockade
beyond antihypertensive effects in patients with arterial hyper-
tension. From a clinical point of view QTc and 24H-HRV may
help risk stratification in patients with arterial hypertension and
may be considered as an underlying rational when choosing
Aldosterone, QTc Prolongation, and Changes in HRVspecific antihypertensive agents and/or combination therapies,
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